Implications of 2-deoxy-D-glucose as a therapeutic molecule in treating COVID-19 patients
Rishit Yokananth, T Lakshmi Prashanth and Yokananth Sekar
As the COVID-19, caused by SARS-CoV-2, rages on as a pandemic throughout the world, India has experienced a large majority of the damage. As a result, multimodal symptomatic therapies were attempted to help COVID patients throughout the world. Since oxygen supply has been running low, scientists were looking for a way to reduce oxygen dependency. 2-deoxy-D-glucose, also known as 2-DG, has presented itself in the scientific community as a drug with numerous beneficial effects on COVID-19 patients, such as reducing dependency on oxygen. This review article is aimed to explain the basics of 2-DG structures, its mode of action, including its possible effects on mast cells (MC), (one cell type that plays a major role in allergic inflammation), its history as a therapeutic agent in humans, and its applications in COVID-19 treatment. Finally, we discuss the principles of clinical trials, the limited scientific evidence available regarding the use of 2-DG in treating COVID-19, what evidence is needed to establish 2-DG as a successful therapeutic for COVID-19 patients, and potential supplemental therapies with 2-DG needing more research.
How to cite this article:
Rishit Yokananth, T Lakshmi Prashanth, Yokananth Sekar. Implications of 2-deoxy-D-glucose as a therapeutic molecule in treating COVID-19 patients. Pharma Innovation 2022;11(1):01-09.